Literature DB >> 24401901

Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer's disease.

Edmond Teng1, Tritia R Yamasaki, Michelle Tran, Julia J Hsiao, David L Sultzer, Mario F Mendez.   

Abstract

BACKGROUND/AIMS: Accurate diagnosis of sporadic early-onset Alzheimer's disease (EOAD) can be challenging, and cerebrospinal fluid (CSF) biomarkers may assist in this process. We compared CSF indices between three EOAD subtypes: amnestic, logopenic progressive aphasia (LPA), and posterior cortical atrophy (PCA).
METHODS: We identified 21 amnestic EOAD, 20 LPA, and 12 PCA patients with CSF data, which included amyloid β1-42 (Aβ42), total tau (t-tau), phospho-tau181 (p-tau), and Aβ42/t-tau index (ATI) levels.
RESULTS: Aβ42 and ATI levels were similar across groups, but t-tau and p-tau levels were significantly lower in PCA patients.
CONCLUSIONS: The Aβ42 and ATI data confirm the commonality of the Aβ pathology in EOAD. The lower tau indices in PCA patients may reflect differences in the distribution of neurofibrillary tangles or rates of neurodegeneration.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24401901      PMCID: PMC4057962          DOI: 10.1159/000355555

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  41 in total

1.  Early-onset dementia is associated with higher mortality.

Authors:  Esther L G E Koedam; Yolande A L Pijnenburg; Dorly J H Deeg; Merel M E Baak; Annelies E van der Vlies; Philip Scheltens; Wiesje M van der Flier
Journal:  Dement Geriatr Cogn Disord       Date:  2008-08-04       Impact factor: 2.959

2.  Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?

Authors:  Lejla Koric; Olivier Felician; Eric Guedj; Anne Michele Hubert; Julien Mancini; Jose Boucraut; Mathieu Ceccaldi
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

3.  CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.

Authors:  Thomas P Baumann; Hüseyin Duyar; Marc Sollberger; Jens Kuhle; Axel Regeniter; Baltazar Gomez-Mancilla; Klaus Schmidtke; Andreas U Monsch
Journal:  Dement Geriatr Cogn Disord       Date:  2010-07-01       Impact factor: 2.959

4.  Multimodal predictors for Alzheimer disease in nonfluent primary progressive aphasia.

Authors:  W T Hu; C McMillan; D Libon; S Leight; M Forman; V M-Y Lee; J Q Trojanowski; M Grossman
Journal:  Neurology       Date:  2010-08-17       Impact factor: 9.910

5.  Syndromes of nonfluent primary progressive aphasia: a clinical and neurolinguistic analysis.

Authors:  Jonathan D Rohrer; Martin N Rossor; Jason D Warren
Journal:  Neurology       Date:  2010-08-17       Impact factor: 9.910

6.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Variability in cognitive presentation of Alzheimer's disease.

Authors:  Cheryl L Stopford; Julie S Snowden; Jennifer C Thompson; David Neary
Journal:  Cortex       Date:  2007-11-17       Impact factor: 4.027

8.  CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Authors:  M I Kester; A E van der Vlies; M A Blankenstein; Y A L Pijnenburg; E J van Elk; P Scheltens; W M van der Flier
Journal:  Neurology       Date:  2009-10-27       Impact factor: 9.910

Review 9.  Total and phosphorylated tau protein as biological markers of Alzheimer's disease.

Authors:  Harald Hampel; Kaj Blennow; Leslie M Shaw; Yvonne C Hoessler; Henrik Zetterberg; John Q Trojanowski
Journal:  Exp Gerontol       Date:  2009-10-22       Impact factor: 4.032

10.  Focal cortical presentations of Alzheimer's disease.

Authors:  S Alladi; J Xuereb; T Bak; P Nestor; J Knibb; K Patterson; J R Hodges
Journal:  Brain       Date:  2007-10       Impact factor: 13.501

View more
  11 in total

1.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Authors:  Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

Review 2.  Primary progressive aphasia: a model for neurodegenerative disease.

Authors:  Boon Lead Tee; Maria Luisa Gorno-Tempini
Journal:  Curr Opin Neurol       Date:  2019-04       Impact factor: 5.710

Review 3.  Early-Onset Alzheimer Disease.

Authors:  Mario F Mendez
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

Review 4.  Early-onset Alzheimer Disease and Its Variants.

Authors:  Mario F Mendez
Journal:  Continuum (Minneap Minn)       Date:  2019-02

5.  Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease.

Authors:  Elias Granadillo; Pongsatorn Paholpak; Mario F Mendez; Edmond Teng
Journal:  Dement Geriatr Cogn Disord       Date:  2017-07-05       Impact factor: 2.959

6.  ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.

Authors:  Katheryn A Q Cousins; David J Irwin; David A Wolk; Edward B Lee; Leslie M J Shaw; John Q Trojanowski; Fulvio Da Re; Garrett S Gibbons; Murray Grossman; Jeffrey S Phillips
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

7.  Reversible dementia: subclinical seizure in early-onset dementia.

Authors:  Elysia Tjong; William McHugh; Yen-Yi Peng
Journal:  Clin Case Rep       Date:  2017-02-06

8.  Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jennifer M Nicholas; Ulf Andreasson; Nadia K Magdalinou; Kaj Blennow; Jason D Warren; Cath J Mummery; Martin N Rossor; Michael P Lunn; Sebastian J Crutch; Nick C Fox; Henrik Zetterberg; Jonathan M Schott
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

9.  Clinical and neuroimaging differences between posterior cortical atrophy and typical amnestic Alzheimer's disease patients at an early disease stage.

Authors:  Guoping Peng; Jianqin Wang; Zhan Feng; Ping Liu; Yafei Zhang; Fangping He; Zhongqin Chen; Kui Zhao; Benyan Luo
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

Review 10.  Biomarkers: Our Path Towards a Cure for Alzheimer Disease.

Authors:  Rawan Tarawneh
Journal:  Biomark Insights       Date:  2020-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.